Loading...
Tilray Brands, Inc.
TLRY•NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$0.36
$-0.02(-6.08%)
Tilray Brands, Inc. (TLRY) Financial Performance & Statements
Review Tilray Brands, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
25.80%
↑ 25.80%
Operating Income Growth
87.24%
↑ 87.24%
Net Income Growth
83.02%
↑ 83.02%
Operating Cash Flow Growth
-490.91%
↓ 490.91%
Operating Margin
-87.77%
↓ 87.77%
Gross Margin
28.58%
↑ 28.58%
Net Profit Margin
-114.39%
↓ 114.39%
ROE
-28.82%
↓ 28.82%
ROIC
-23.10%
↓ 23.10%
Tilray Brands, Inc. (TLRY) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Tilray Brands, Inc. stock.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $210.95M | $200.04M | $229.88M | $188.34M |
| Cost of Revenue | $149.73M | $140.34M | $166.58M | $160.50M |
| Gross Profit | $61.22M | $59.71M | $63.30M | $27.84M |
| Gross Profit Ratio | $0.29 | $0.30 | $0.28 | $0.15 |
| R&D Expenses | $60000.00 | $105000.00 | $394000.00 | $106000.00 |
| SG&A Expenses | $62.16M | $67.39M | $83.50M | $61.13M |
| Operating Expenses | $103.44M | $96.28M | $83.90M | $61.23M |
| Total Costs & Expenses | $253.17M | $236.61M | $250.48M | $221.73M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $7.77M | $9.84M | $22.29M | $8.52M |
| Depreciation & Amortization | $34.05M | $31.81M | $31.73M | $32.84M |
| EBITDA | -$41.42M | $7.89M | $11.01M | -$82.10M |
| EBITDA Ratio | -$0.20 | $0.04 | $0.05 | -$0.44 |
| Operating Income | -$42.22M | -$36.57M | -$20.60M | -$33.39M |
| Operating Income Ratio | -$0.20 | -$0.18 | -$0.09 | -$0.18 |
| Other Income/Expenses (Net) | -$41.02M | $2.80M | -$20.49M | $3.57M |
| Income Before Tax | -$83.24M | -$33.77M | -$43.004M | -$107.85M |
| Income Before Tax Ratio | -$0.39 | -$0.17 | -$0.19 | -$0.57 |
| Income Tax Expense | $2.04M | $886000.00 | -$27.63M | -$2.87M |
| Net Income | -$85.28M | -$39.16M | -$31.75M | -$92.70M |
| Net Income Ratio | -$0.40 | -$0.20 | -$0.14 | -$0.49 |
| EPS | -$0.10 | -$0.04 | -$0.04 | -$0.12 |
| Diluted EPS | -$0.10 | -$0.04 | -$0.04 | -$0.12 |
| Weighted Avg Shares Outstanding | $864.97M | $875.44M | $793.67M | $754.44M |
| Weighted Avg Shares Outstanding (Diluted) | $864.97M | $875.44M | $793.67M | $754.44M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan